Business

Light-activated cancer drugs without toxic side effects: fresh insight

Future cancer drugs that are activated by light and don’t cause the toxic side-effects of current chemotherapy treatments are closer to becoming a reality, thanks to new research made possible by the Monash Warwick Alliance, an intercontinental collaboration between the University of Warwick (UK) and Monash University (Australia).

TC BioPharm and the NIPRO Corporation announce strategic programme co-developing a novel gamma-delta CAR-T product to treat cancer

The NIPRO Corporation (TSE: 8086) and TC BioPharm Ltd (TCB) announced today that they have formed a strategic collaboration to co-develop a novel immunotherapy product using TCB's safe CAR-T platform, based on unique properties of modified gamma delta (γδ) T cells to selectively target cancer whilst leaving healthy cells untouched. TCB intends to use this novel platform to develop new CAR-based immunotherapies, with the aim of treating a broad range of cancers and major viral disease.

Guidelines extended to improve the use of feedback from patients in clinical trials

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treatment on participating patients and their quality of life. Protocols describe how a clinical trial will be conducted, including its objectives, design, methodology, statistical considerations and organisation, and ensures the safety of participating patients as well as the integrity of the data collected.

Merck celebrates its 350th anniversary

Merck, a leading science and technology company, will celebrate its 350th anniversary this year with customers, partners and employees under the motto "Past. Present. Future." In 1668, the pharmacist Friedrich Jacob Merck laid the cornerstone for what Merck is today - a vibrant, global science and technology company.

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of €45 in cash, which represents an aggregate equity value of approximately €3.9 billion.

AstraZeneca listed as one of the world's top-100 most sustainable companies and recognised for its three-fold increase in renewable energy usage

AstraZeneca has been recognised for its commitment to sustainability with two new, global accolades: the company has been listed as one of the 100 most sustainable companies in the world by Corporate Knights, the Toronto-based media and investment advisory firm, and has been commended for its use of renewable energy, as one of 122 multinational businesses who have made the RE100 commitment, by The Climate Group, an international non-profit organisation focused on accelerating climate action.

MSD Innovation Factory Selects 3 Companies to co-Create Digital Health Solutions

Throughout the MSD Innovation Factory, MSD launched 7 health-related challenges to award the three most outstanding solutions. Blendarsys, Symptoma and Grupo Pulso are the winners out of 100 proposals. The companies will receive up to $20,000 each to co-create and roll-out their solution with MSD support.

Business

More Pharma News ...